TY - JOUR
T1 - Low-dose dihydrotestosterone drives metabolic dysfunction via cytosolic and nuclear hepatic androgen receptor mechanisms
AU - Andrisse, Stanley
AU - Childress, Shameka
AU - Ma, Yaping
AU - Billings, Katelyn
AU - Chen, Yi
AU - Xue, Ping
AU - Stewart, Ashley
AU - Sonko, Momodou L.
AU - Wolfe, Andrew
AU - Wu, Sheng
N1 - Funding Information:
This work was supported by the National Institutes of Health (Grants R00-HD068130 to S.W. and 5T32DK007751-18 to S.A.). This work was also supported by the Baltimore Diabetes Research Center: Pilots and Feasibility Grant (to S.W.). Technical support was provided by the Integrated Physiology Core of the Baltimore DRTC (P60DK079637).
Publisher Copyright:
© 2017 by the Endocrine Society.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Androgen excess in women is associated with metabolic dysfunction (e.g., obesity, hyperinsulinemia, insulin resistance, and increased risk of type 2 diabetes) and reproductive dysfunction (e.g., polycystic ovaries, amenorrhea, dysregulated gonadotropin release, and infertility). We sought to identify the effects of androgen excess on glucose metabolic dysfunction and the specific mechanisms of action by which androgens are inducing pathology. We developed a mouse model that displayed pathophysiological serum androgen levels with normal bodymass/composition to ensure that the phenotypes were directly fromandrogens and not an indirect consequence of obesity. We performed reproductive tests, metabolic tests, and hormonal assays. Liverswere isolated and examined viamolecular, biochemical, and histological analysis. Additionally, a low-dose dihydrotestosterone (DHT) cell model using H2.35 mouse hepatocytes was developed to study androgen effects on hepatic insulin signaling. DHT mice demonstrated impaired estrous cyclicity; few corpora lutea in the ovaries; glucose, insulin, and pyruvate intolerance; and lowered hepatic insulin action. Mechanistically, DHT increased hepatic androgen-receptor binding to phosphoinositide-3-kinase (PI3K)-p85, resulting in dissociation of PI3K-p85 from PI3K-p110, leading to reduced PI3K activity and decreased p-AKT and, thus, lowered insulin action. DHT increased gluconeogenesis via direct transcriptional regulation of gluconeogenic enzymes and coactivators. The hepatocyte model recapitulated the in vivo findings. The DHT-induced hepatocyte insulin resistance was reversed by the androgenreceptor antagonist, flutamide. These findings present a phenotype (i.e., impaired glucose tolerance and disrupted glucose metabolism) in a lean hyperandrogenemia model (low-dose DHT) and data to support 2 molecular mechanisms that help drive androgen-induced impaired glucose metabolism.
AB - Androgen excess in women is associated with metabolic dysfunction (e.g., obesity, hyperinsulinemia, insulin resistance, and increased risk of type 2 diabetes) and reproductive dysfunction (e.g., polycystic ovaries, amenorrhea, dysregulated gonadotropin release, and infertility). We sought to identify the effects of androgen excess on glucose metabolic dysfunction and the specific mechanisms of action by which androgens are inducing pathology. We developed a mouse model that displayed pathophysiological serum androgen levels with normal bodymass/composition to ensure that the phenotypes were directly fromandrogens and not an indirect consequence of obesity. We performed reproductive tests, metabolic tests, and hormonal assays. Liverswere isolated and examined viamolecular, biochemical, and histological analysis. Additionally, a low-dose dihydrotestosterone (DHT) cell model using H2.35 mouse hepatocytes was developed to study androgen effects on hepatic insulin signaling. DHT mice demonstrated impaired estrous cyclicity; few corpora lutea in the ovaries; glucose, insulin, and pyruvate intolerance; and lowered hepatic insulin action. Mechanistically, DHT increased hepatic androgen-receptor binding to phosphoinositide-3-kinase (PI3K)-p85, resulting in dissociation of PI3K-p85 from PI3K-p110, leading to reduced PI3K activity and decreased p-AKT and, thus, lowered insulin action. DHT increased gluconeogenesis via direct transcriptional regulation of gluconeogenic enzymes and coactivators. The hepatocyte model recapitulated the in vivo findings. The DHT-induced hepatocyte insulin resistance was reversed by the androgenreceptor antagonist, flutamide. These findings present a phenotype (i.e., impaired glucose tolerance and disrupted glucose metabolism) in a lean hyperandrogenemia model (low-dose DHT) and data to support 2 molecular mechanisms that help drive androgen-induced impaired glucose metabolism.
UR - http://www.scopus.com/inward/record.url?scp=85014455479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014455479&partnerID=8YFLogxK
U2 - 10.1210/en.2016-1553
DO - 10.1210/en.2016-1553
M3 - Article
C2 - 27967242
AN - SCOPUS:85014455479
SN - 0013-7227
VL - 158
SP - 531
EP - 544
JO - Endocrinology
JF - Endocrinology
IS - 3
ER -